Beam Therapeutics (BEAM) Equity Average (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Equity Average data on file, last reported at $1.2 billion in Q1 2026.

• Quarterly Equity Average rose 28.97% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 28.97% YoY) and the FY2025 annual result came in at $986.0 million, up 14.99% from the prior year.
• Equity Average advanced to $1.2 billion in Q1 2026 per BEAM's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Equity Average topped out at $1.2 billion in Q1 2026 and bottomed at $724.0 million in Q4 2022.
• The 5-year median for Equity Average is $827.9 million (2022), against an average of $887.0 million.
• Peak annual rise in Equity Average reached 147.88% in 2022, while the deepest fall reached 13.84% in 2022.
• Tracing BEAM's Equity Average over 5 years: stood at $724.0 million in 2022, then increased by 21.57% to $880.1 million in 2023, then dropped by 13.37% to $762.4 million in 2024, then soared by 44.56% to $1.1 billion in 2025, then climbed by 9.0% to $1.2 billion in 2026.
• Per Business Quant, the three latest BEAM Equity Average figures stand at $1.2 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.0 billion (Q3 2025).

Peer Comparison